“There are big changes ahead, not least the impact of the UK’s exit from the EU, but I am confident that the Agency, with its globally unique concentration of expertise in data, standards and regulation will continue to offer our customers a full range of services an d products which is not replicated anywhere else in the world”, Sir Michael Rawlins GBE Chairman of MHRA, said.

The three centres – the Clinical Practice Research Datalink, the MHRA regulator, and the National Institute for Biological Standards and Control – bring together expertise and evidence so that:

• clinical practice is informed by and contributes to regulatory evidence;
• global standards are underpinned by and enhance regulation; and
• real world data additionally underpins regulation.

The combination of these should bring real benefit to patients across the UK, enabling the Agency to protect public health and to improve lives.

The MHRA’s opportunity through this new 5-year Corporate Plan, particularly in the context of the UK’s exit from the EU, will be to:

• build further on the unique offer to the UK and international customers;
• set out the ambitions on the added value which the Agency brings to improving public health; and
• highlight the Agency’s contribution to delivering the Government’s Life Sciences agenda, notably in clinical trials, accelerated product licensing and emerging areas like genomics and advanced therapies.

This plan, then, sets direction on what the Agency will do over the next five years, to address proactively the uncertainties they face. It positions the MHRA to be agile to meet the changes that lie ahead and to continue to deliver innovative science and first-class research.

Source:

MHRA Corporate Plan